MedTrace Logo

Methotrexate Treatment in Cases of Ectopic Pregnancy With Relative Contraindications

NCT07186127 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 230

Last updated 2025-09-22

No results posted yet for this study

Summary

Study Description (For Patients, Families, and Healthcare Providers)

Purpose:

The aim of this study is to evaluate the effectiveness and safety of methotrexate treatment in women with ectopic pregnancy who belong to a group for whom this treatment is relatively contraindicated.

Background:

Methotrexate is a medication commonly used in the treatment of ectopic pregnancy (a pregnancy that occurs outside the uterus, usually in the fallopian tube). However, in certain conditions - such as kidney or liver dysfunction - methotrexate use may carry increased risks. These situations are known as relative contraindications. This study will retrospectively examine treatment outcomes in this specific patient population.

Method:

The study will analyze medical records of patients who were previously treated with methotrexate for ectopic pregnancy. No new interventions will be performed. The analysis will be based solely on existing clinical data.

Why Is This Important? The findings of this study may help us better understand the safety limits of methotrexate therapy and guide healthcare providers in managing similar cases in the future.

Conditions

Interventions

DRUG

Drug: Methotrexate (MTX) Patients received methotrexate treatment according to institutional protocols. Dosage and administration routes were recorded retrospectively. For patients who did not respond

MTX medical treatment Laparoscopic salpingectomy Laparoscopic salpingostomy

Sponsors & Collaborators

  • Bagcilar Training and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • gülhan özüm, md · Sağlık Bilimleri Üniversitesi, Bağcılar Eğitim ve Araştırma Hastanesi

Eligibility

Min Age
18 Years
Max Age
48 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2025-09-30
Completion
2026-05-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07186127 on ClinicalTrials.gov